{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:25:00Z","timestamp":1793269500049,"version":"4.5.0"},"reference-count":152,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/02"],"award-info":[{"award-number":["MC_UU_00004\/02"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2023,8,30]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Advances in the detection and treatment of cancer have translated into improved cancer survival rates and a growing population of cancer survivors. These include those living with cancer and individuals free of the disease following treatment. Epidemiological studies demonstrate that cancer survivors are at an increased risk of cardiovascular disease (CVD), with cardiovascular (CV) mortality overtaking cancer mortality in some tumour types. Cancer and CVD share common aetiological risk factors, for example, age, tobacco use and obesity, as well as a shared inflammatory pathogenesis. The CV risks of mediastinal radiotherapy and chemotherapy, first observed in the 1970s with anthracyclines, have long been appreciated. More recently, targeted anticancer therapeutics (human epidermal growth factor receptor-2 targeted therpies, vascular endothelial growth factor inhibitors, second\/third-generation BCR-ABL inhibitors, multiple myeloma therapies and combination RAF and MEK inhibitors in particular) as well as immunotherapies have added to the burden of treatment-related CV toxicity. Additionally, cancer therapy may indirectly impact on CV health by decreasing physical activity, increasing weight gain and accelerating the ageing process. Improving overall health outcomes by considering cardiological prevention and management in cancer survivorship is an area of increasing interest. CV risk factor assessment and management are recommended post-cancer treatment in accordance with primary prevention guidelines. The European Society of Cardiology 2022 guidelines also recommend enhanced surveillance after cancer treatments with a moderate to high risk of CV consequences. The aim of this article is to provide an overview of the interconnections between cancer and CVD, review current survivorship recommendations, and highlight key areas of ongoing and future research.<\/jats:p>","DOI":"10.1136\/bmjonc-2023-000090","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T10:35:46Z","timestamp":1697193346000},"page":"e000090","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Cardiovascular health: an important component of cancer survivorship"],"prefix":"10.1136","volume":"2","clinical-trial-number":[{"clinical-trial-number":"nct01327846","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02039622","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1741-478X","authenticated-orcid":false,"given":"Siobhan","family":"Cleary","sequence":"first","affiliation":[{"name":"MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK"},{"name":"Department of Cancer and Surgery, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D","family":"Rosen","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan C","family":"Gilbert","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E","family":"Langley","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"2025090109205860000_2.1.e000090.1","unstructured":"CRUK . Cancer statistics for the UK: cancer research UK, Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics-for-the-uk"},{"key":"2025090109205860000_2.1.e000090.2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0133"},{"key":"2025090109205860000_2.1.e000090.3","first-page":"409","article-title":"Cancer treatment Andsurvivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025090109205860000_2.1.e000090.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1425"},{"key":"2025090109205860000_2.1.e000090.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30800-9"},{"key":"2025090109205860000_2.1.e000090.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4351","article-title":"Long term cause specific mortality among 34 489 five year survivors of childhood cancer in great Britain: population based cohort study","volume":"354","author":"Fidler","year":"2016","journal-title":"BMJ"},{"key":"2025090109205860000_2.1.e000090.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15639-5","article-title":"Fatal heart disease among cancer patients","volume":"11","author":"Stoltzfus","year":"2020","journal-title":"Nat Commun"},{"key":"2025090109205860000_2.1.e000090.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31674-5"},{"key":"2025090109205860000_2.1.e000090.9","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2022-321888"},{"key":"2025090109205860000_2.1.e000090.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0409"},{"key":"2025090109205860000_2.1.e000090.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz766"},{"key":"2025090109205860000_2.1.e000090.12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaccao.2022.01.102","article-title":"Does cardiovascular mortality overtake cancer mortality during cancer survivorship?: an English retrospective cohort study","volume":"4","author":"Strongman","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2025090109205860000_2.1.e000090.13","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1093\/eurheartj\/ehz781","article-title":"From trends to transformation: where cardio-oncology is to make a difference","volume":"40","author":"Herrmann","year":"2019","journal-title":"Eur Heart J"},{"key":"2025090109205860000_2.1.e000090.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.01.038"},{"key":"2025090109205860000_2.1.e000090.15","unstructured":"CRUK . Cancer incidence by age: cancer research UK, . 2021 Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence\/age"},{"key":"2025090109205860000_2.1.e000090.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0721-1"},{"key":"2025090109205860000_2.1.e000090.17","unstructured":"British Heart Foundation . BHF (2023) analysis of official UK mortality data. 2023. Available: https:\/\/www.bhf.org.uk\/-\/media\/files\/for-professionals\/research\/heart-statistics\/bhf-statistics-compendium-2023.pdf"},{"key":"2025090109205860000_2.1.e000090.18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061400","article-title":"Cancer and aging: two tightly interconnected biological processes","volume":"13","author":"Berben","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025090109205860000_2.1.e000090.19","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/jnci\/djz136","article-title":"Measuring aging and identifying aging phenotypes in cancer survivors","volume":"111","author":"Guida","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025090109205860000_2.1.e000090.20","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000250","article-title":"Biology of premature ageing in survivors of cancer","volume":"2","author":"Cupit-Link","year":"2017","journal-title":"ESMO Open"},{"key":"2025090109205860000_2.1.e000090.21","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.931917","article-title":"Shared genetic risk factors between cancer and cardiovascular diseases","volume":"9","author":"Turk","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025090109205860000_2.1.e000090.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.06.007"},{"key":"2025090109205860000_2.1.e000090.23","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1002\/cam4.4647","article-title":"Global, regional, and national burden of cancers attributable to tobacco smoking in 204 countries and territories, 1990-2019","volume":"11","author":"Safiri","year":"2022","journal-title":"Cancer Med"},{"key":"2025090109205860000_2.1.e000090.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"2025090109205860000_2.1.e000090.25","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.300156"},{"key":"2025090109205860000_2.1.e000090.26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41568-021-00423-4","article-title":"Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention","volume":"22","author":"Hecht","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2025090109205860000_2.1.e000090.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020406"},{"key":"2025090109205860000_2.1.e000090.28","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/nxz268"},{"key":"2025090109205860000_2.1.e000090.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003198","article-title":"The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: an analysis of the global burden of disease study","volume":"17","author":"Dai","year":"2020","journal-title":"PLoS Med"},{"key":"2025090109205860000_2.1.e000090.30","unstructured":"World Health Organization . WHO European regional obesity report 2022. Regional Office for Europe; 2022."},{"key":"2025090109205860000_2.1.e000090.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614362"},{"key":"2025090109205860000_2.1.e000090.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01438-6"},{"key":"2025090109205860000_2.1.e000090.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1606602"},{"key":"2025090109205860000_2.1.e000090.34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.metabol.2018.10.011","article-title":"Obesity and cardiovascular disease: revisiting an old relationship","volume":"92","author":"Koliaki","year":"2019","journal-title":"Metabolism"},{"key":"2025090109205860000_2.1.e000090.35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/1878-0261.12772","article-title":"Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms","volume":"15","author":"Friedenreich","year":"2021","journal-title":"Mol Oncol"},{"key":"2025090109205860000_2.1.e000090.36","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-1245"},{"key":"2025090109205860000_2.1.e000090.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.005"},{"key":"2025090109205860000_2.1.e000090.38","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-019-1133-9","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"21","author":"Htay","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2025090109205860000_2.1.e000090.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61031-9"},{"key":"2025090109205860000_2.1.e000090.40","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2020-102955"},{"key":"2025090109205860000_2.1.e000090.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.10.025"},{"key":"2025090109205860000_2.1.e000090.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0065-1"},{"key":"2025090109205860000_2.1.e000090.43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4391"},{"key":"2025090109205860000_2.1.e000090.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.9014"},{"key":"2025090109205860000_2.1.e000090.45","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000461"},{"key":"2025090109205860000_2.1.e000090.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.05.031"},{"key":"2025090109205860000_2.1.e000090.47","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1177\/2047487320930873","article-title":"Cardiorespiratory fitness and survival following cancer diagnosis","volume":"28","author":"Fardman","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2025090109205860000_2.1.e000090.48","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10654-019-00575-6","article-title":"Association between cardiorespiratory fitness and colorectal cancer in the UK biobank","volume":"35","author":"Hillreiner","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"2025090109205860000_2.1.e000090.49","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ehjqcco\/qcaa015","article-title":"Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer","volume":"6","author":"Groarke","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025090109205860000_2.1.e000090.50","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaccao.2021.08.011","article-title":"Common pathophysiology in cancer, atrial fibrillation, atherosclerosis, and thrombosis: JACC: Cardiooncology state-of-the-art review","volume":"3","author":"Leiva","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2025090109205860000_2.1.e000090.51","doi-asserted-by":"crossref","first-page":"704106","DOI":"10.3389\/fcvm.2021.704106","article-title":"Smoking and the pathophysiology of peripheral artery disease","volume":"8","author":"Wang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025090109205860000_2.1.e000090.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.06.001"},{"key":"2025090109205860000_2.1.e000090.53","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz058"},{"key":"2025090109205860000_2.1.e000090.54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-743187"},{"key":"2025090109205860000_2.1.e000090.55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jacc.2022.04.034","article-title":"Association of thromboxane generation with survival in aspirin users and nonusers","volume":"80","author":"Rade","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025090109205860000_2.1.e000090.56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306301"},{"key":"2025090109205860000_2.1.e000090.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.09.009"},{"key":"2025090109205860000_2.1.e000090.58","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000104566.10178.AF"},{"key":"2025090109205860000_2.1.e000090.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704033361401"},{"key":"2025090109205860000_2.1.e000090.60","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure","volume":"17","author":"Adamo","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2025090109205860000_2.1.e000090.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"2025090109205860000_2.1.e000090.62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32247-X"},{"key":"2025090109205860000_2.1.e000090.63","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT037","article-title":"Abstract Ct037: Canakinumab in combination with first-line (1L) Pembrolizumab plus chemotherapy for advanced non-small cell lung cancer (Ansclc): results from the CANOPY-1 phase 3 trial","volume":"82","author":"Tan","year":"2022","journal-title":"Cancer Research"},{"key":"2025090109205860000_2.1.e000090.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.04.088"},{"key":"2025090109205860000_2.1.e000090.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.04.053"},{"key":"2025090109205860000_2.1.e000090.66","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.472"},{"key":"2025090109205860000_2.1.e000090.67","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/hr.2017.45","article-title":"Does the pathophysiology of heart failure prime the incidence of cancer","volume":"40","author":"Sakamoto","year":"2017","journal-title":"Hypertens Res"},{"key":"2025090109205860000_2.1.e000090.68","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1539"},{"key":"2025090109205860000_2.1.e000090.69","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.033603"},{"key":"2025090109205860000_2.1.e000090.70","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3015"},{"key":"2025090109205860000_2.1.e000090.71","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.030816"},{"key":"2025090109205860000_2.1.e000090.72","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.046471"},{"key":"2025090109205860000_2.1.e000090.73","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071767","article-title":"Renin-angiotensin-aldosterone system and Immunomodulation: a state-of-the-art review","volume":"10","author":"Laghlam","year":"2021","journal-title":"Cells"},{"key":"2025090109205860000_2.1.e000090.74","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02170-0"},{"key":"2025090109205860000_2.1.e000090.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0964-7"},{"key":"2025090109205860000_2.1.e000090.76","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"2025090109205860000_2.1.e000090.77","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2015.65"},{"key":"2025090109205860000_2.1.e000090.78","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13775"},{"key":"2025090109205860000_2.1.e000090.79","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777"},{"key":"2025090109205860000_2.1.e000090.80","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11407"},{"key":"2025090109205860000_2.1.e000090.81","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA) the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2025090109205860000_2.1.e000090.82","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41416-020-01049-3","article-title":"Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy","volume":"123","author":"Stelwagen","year":"2020","journal-title":"Br J Cancer"},{"key":"2025090109205860000_2.1.e000090.83","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2025090109205860000_2.1.e000090.84","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.6004\/jnccn.2019.7369","article-title":"Testicular cancer survivorship","volume":"17","author":"Fung","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2025090109205860000_2.1.e000090.85","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2017.77.0735","article-title":"Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study","volume":"36","author":"Kerns","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025090109205860000_2.1.e000090.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.07.004"},{"key":"2025090109205860000_2.1.e000090.87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.2497"},{"key":"2025090109205860000_2.1.e000090.88","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k3845","article-title":"Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review","volume":"363","author":"Matthews","year":"2018","journal-title":"BMJ"},{"key":"2025090109205860000_2.1.e000090.89","doi-asserted-by":"crossref","unstructured":"Okwuosa TM , Morgans A , Rhee J-W , et al . Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American heart association. Circ: Genomic and Precision Medicine 2021;14. doi:10.1161\/HCG.0000000000000082","DOI":"10.1161\/HCG.0000000000000082"},{"key":"2025090109205860000_2.1.e000090.90","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw673"},{"key":"2025090109205860000_2.1.e000090.91","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-017-0658-x","article-title":"Radiation-induced cardiovascular disease","volume":"19","author":"Raghunathan","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"2025090109205860000_2.1.e000090.92","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw359"},{"key":"2025090109205860000_2.1.e000090.93","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1209825","article-title":"Ischemic heart disease after breast cancer radiotherapy","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"2025090109205860000_2.1.e000090.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.04.093"},{"key":"2025090109205860000_2.1.e000090.95","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11912-021-01114-x","article-title":"Cardiovascular toxicity of novel Her2-targeted therapies in the treatment of breast cancer","volume":"23","author":"Dent","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2025090109205860000_2.1.e000090.96","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","article-title":"A pooled analysis of the cardiac events in the Trastuzumab adjuvant trials","volume":"179","author":"de Azambuja","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2025090109205860000_2.1.e000090.97","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000073","article-title":"Twenty years of anti-HER2 therapy-associated cardiotoxicity","volume":"1","author":"Pond\u00e9","year":"2016","journal-title":"ESMO Open"},{"key":"2025090109205860000_2.1.e000090.98","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.17"},{"key":"2025090109205860000_2.1.e000090.99","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2025090109205860000_2.1.e000090.100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025090109205860000_2.1.e000090.101","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.675811","article-title":"Cardiovascular issues in tyrosine kinase inhibitors treatments for chronic myeloid leukemia: a review","volume":"12","author":"Santoro","year":"2021","journal-title":"Front Physiol"},{"key":"2025090109205860000_2.1.e000090.102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"2025090109205860000_2.1.e000090.103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2025090109205860000_2.1.e000090.104","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","article-title":"The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview","volume":"23","author":"Giraud","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025090109205860000_2.1.e000090.105","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"2025090109205860000_2.1.e000090.106","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.jtho.2021.07.030","article-title":"Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC","volume":"16","author":"Waliany","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025090109205860000_2.1.e000090.107","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"2025090109205860000_2.1.e000090.108","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025090109205860000_2.1.e000090.109","article-title":"The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: including myocarditis and the new entity of non inflammatory left ventricular dysfunction","volume":"8","author":"Andres","year":"2022","journal-title":"Cardiooncology"},{"key":"2025090109205860000_2.1.e000090.110","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"2025090109205860000_2.1.e000090.111","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2025090109205860000_2.1.e000090.112","doi-asserted-by":"crossref","DOI":"10.3390\/cells9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice","volume":"9","author":"Poels","year":"2020","journal-title":"Cells"},{"key":"2025090109205860000_2.1.e000090.113","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.930797","article-title":"Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac damps fibronectin-EDA, S100\/Calgranulin, Galectine-3, and NLRP3-myd88-chemokine pathways","volume":"9","author":"Quagliariello","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025090109205860000_2.1.e000090.114","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: Cardiooncology primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2025090109205860000_2.1.e000090.115","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"key":"2025090109205860000_2.1.e000090.116","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025090109205860000_2.1.e000090.117","article-title":"Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports","volume":"8","author":"Ewer","year":"2022","journal-title":"Cardiooncology"},{"key":"2025090109205860000_2.1.e000090.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.023"},{"key":"2025090109205860000_2.1.e000090.119","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.5400"},{"key":"2025090109205860000_2.1.e000090.120","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.6004\/jnccn.2020.0037","article-title":"NCCN guidelines insights: survivorship, version 2.2020","volume":"18","author":"Denlinger","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025090109205860000_2.1.e000090.121","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7861\/clinmedicine.17-4-293","article-title":"Monitoring risk factors of cardiovascular disease in cancer survivors","volume":"17","author":"Kapoor","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"2025090109205860000_2.1.e000090.122","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0070","article-title":"Assessment and management of cardiovascular risk factors among US veterans with prostate cancer","volume":"4","author":"Sun","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025090109205860000_2.1.e000090.123","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/pon.5054","article-title":"Quality of life versus length of life considerations in cancer patients: a systematic literature review","volume":"28","author":"Shrestha","year":"2019","journal-title":"Psychooncology"},{"key":"2025090109205860000_2.1.e000090.124","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-oncology study group of the heart failure association of the European society of cardiology in collaboration with the international cardio-oncology society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025090109205860000_2.1.e000090.125","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06192-w"},{"key":"2025090109205860000_2.1.e000090.126","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2021.11.059","article-title":"Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: the HFA\/ICOS risk tool in real-world practice","volume":"349","author":"Tini","year":"2022","journal-title":"Int J Cardiol"},{"key":"2025090109205860000_2.1.e000090.127","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ehf2.13897","article-title":"The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity","volume":"9","author":"Di Lisi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2025090109205860000_2.1.e000090.128","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030847","article-title":"Evaluation of risk prediction models to identify cancer therapeutics related cardiac dysfunction in women with HER2+ breast cancer","volume":"11","author":"Suntheralingam","year":"2022","journal-title":"J Clin Med"},{"key":"2025090109205860000_2.1.e000090.129","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2022.0088"},{"key":"2025090109205860000_2.1.e000090.130","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.736854","article-title":"Risk factors for anthracycline-induced cardiotoxicity","volume":"8","author":"Qiu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025090109205860000_2.1.e000090.131","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/eurjpc\/zwaa034","article-title":"Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry","volume":"29","author":"Caro-Cod\u00f3n","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2025090109205860000_2.1.e000090.132","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cncr.32690","article-title":"Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events","volume":"126","author":"Hershman","year":"2020","journal-title":"Cancer"},{"key":"2025090109205860000_2.1.e000090.133","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-016-4043-1","article-title":"Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors","volume":"161","author":"Calip","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2025090109205860000_2.1.e000090.134","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.032047"},{"key":"2025090109205860000_2.1.e000090.135","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jaccao.2021.09.016","article-title":"The role of healthy lifestyle in cancer incidence and temporal transitions to cardiometabolic disease","volume":"3","author":"Cao","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2025090109205860000_2.1.e000090.136","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamaoncol.2018.0126","article-title":"Association of survival with adherence to the American cancer society nutrition and physical activity guidelines for cancer survivors after colon cancer diagnosis: the CALGB 89803\/alliance trial","volume":"4","author":"Van Blarigan","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025090109205860000_2.1.e000090.137","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2022.101011","article-title":"Surviving and thriving: what do survivors of gynecologic cancer want","volume":"41","author":"Peerenboom","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"2025090109205860000_2.1.e000090.138","unstructured":"World Cancer Research Fund\/ American Institute for Cancer Research . Survivors of breast and other cancers. 2018. Available: https:\/\/www.wcrf.org\/wp-content\/uploads\/2021\/02\/Cancer-Survivors.pdf"},{"key":"2025090109205860000_2.1.e000090.139","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21719"},{"key":"2025090109205860000_2.1.e000090.140","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"2025090109205860000_2.1.e000090.141","unstructured":"WHO . World health organization fact sheets: physical activity. 2022. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/physical-activity [Accessed 05 Oct 2022]."},{"key":"2025090109205860000_2.1.e000090.142","article-title":"Physical activity for women with breast cancer after adjuvant therapy","volume":"1","author":"Lahart","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090109205860000_2.1.e000090.143","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17155351","article-title":"Exercise levels and preferences in cancer patients: a cross-sectional study","volume":"17","author":"Avancini","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2025090109205860000_2.1.e000090.144","doi-asserted-by":"crossref","DOI":"10.1136\/bjsports-2017-098285","article-title":"Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials","volume":"52","author":"Fuller","year":"2018","journal-title":"Br J Sports Med"},{"key":"2025090109205860000_2.1.e000090.145","article-title":"High-intensity interval training improves cardiorespiratory fitness in cancer patients and survivors: a meta-analysis","volume":"29","author":"Wallen","year":"2020","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2025090109205860000_2.1.e000090.146","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaccao.2019.08.014","article-title":"Pre-diagnosis exercise and cardiovascular events in primary breast cancer: women\u2019s health initiative","volume":"1","author":"Okwuosa","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2025090109205860000_2.1.e000090.147","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.7511"},{"key":"2025090109205860000_2.1.e000090.148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.6603"},{"key":"2025090109205860000_2.1.e000090.149","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.998275"},{"key":"2025090109205860000_2.1.e000090.150","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu012"},{"key":"2025090109205860000_2.1.e000090.151","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000679"},{"key":"2025090109205860000_2.1.e000090.152","article-title":"Exercise-based cardiac rehabilitation for coronary heart disease","volume":"11","author":"Dibben","year":"2021","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2023-000090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:21:19Z","timestamp":1756743679000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2023-000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":152,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,13]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjonc-2023-000090"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2023-000090","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}